Ken Liao

624 total citations
26 papers, 471 citations indexed

About

Ken Liao is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Ken Liao has authored 26 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Cancer Research. Recurrent topics in Ken Liao's work include Biosimilars and Bioanalytical Methods (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Effects and risks of endocrine disrupting chemicals (4 papers). Ken Liao is often cited by papers focused on Biosimilars and Bioanalytical Methods (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Effects and risks of endocrine disrupting chemicals (4 papers). Ken Liao collaborates with scholars based in United States, China and Belgium. Ken Liao's co-authors include Harvey J. Clewell, Yu‐Mei Tan, Rory B. Conolly, Benjamin C. Blount, Cheng-Chun Lee, Calvin Yu‐Chian Chen, Kuen‐Bao Chen, Mao-Feng Sun, Wen‐Yuan Lee and Tianya Li and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Plant Science and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ken Liao

21 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Liao United States	10	209	108	105	68	46	26	471
Abby Jacobs United States	7	110 0.5×	137 1.3×	207 2.0×	48 0.7×	38 0.8×	7	401
Jennifer Y. Tanir United States	11	283 1.4×	246 2.3×	325 3.1×	154 2.3×	19 0.4×	17	760
Tetyana Kobets United States	13	109 0.5×	161 1.5×	194 1.8×	72 1.1×	15 0.3×	26	439
Albrecht Poth Germany	11	158 0.8×	165 1.5×	188 1.8×	64 0.9×	27 0.6×	21	439
Hao Le Thi Hong United States	13	190 0.9×	311 2.9×	230 2.2×	103 1.5×	149 3.2×	24	721
Kim Vande Loock Belgium	12	240 1.1×	261 2.4×	329 3.1×	96 1.4×	27 0.6×	15	610
Connie L. Chen United States	12	156 0.7×	122 1.1×	118 1.1×	25 0.4×	19 0.4×	27	489
Elisavet Gatzidou Greece	10	155 0.7×	217 2.0×	91 0.9×	36 0.5×	49 1.1×	13	506
Brandy Beverly United States	10	270 1.3×	96 0.9×	63 0.6×	14 0.2×	24 0.5×	14	512
D. L. Musgrove United States	13	88 0.4×	45 0.4×	70 0.7×	60 0.9×	15 0.3×	22	378

Countries citing papers authored by Ken Liao

Since Specialization

Citations

This map shows the geographic impact of Ken Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Liao more than expected).

Fields of papers citing papers by Ken Liao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Liao. The network helps show where Ken Liao may publish in the future.

Co-authorship network of co-authors of Ken Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Liao. A scholar is included among the top collaborators of Ken Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Liao. Ken Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghasemi, Mohammad, Ji Yun Kim, Lisa Seitz, et al.. (2025). Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants. British Journal of Clinical Pharmacology. 91(12). 3366–3377.

Liao, Ken, et al.. (2025). The triglyceride glucose-body mass index predicts adverse reproductive outcomes in women with polycystic ovary syndrome undergoing frozen embryo transfer. Frontiers in Endocrinology. 16. 1629837–1629837.

Li, Chunyan, Ling Zhao, Wei Li, et al.. (2024). Investigation of normal zone propagation velocity in AgSn/Ag/Ba122 superconducting tapes using a conduction cooling test system. Superconductor Science and Technology. 37(8). 85021–85021.

Williams, Jason H., et al.. (2024). Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework. The AAPS Journal. 26(2). 31–31.

Liao, Ken, et al.. (2022). Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates. The AAPS Journal. 24(4). 73–73. 2 indexed citations

Williams, Jason H., et al.. (2022). Antibody-drug conjugate (ADC) joint disposition properties and their clinical utilities for comparative assessments in terms of favorable pharmacokinetic (PK) characteristics.. Journal of Clinical Oncology. 40(16_suppl). e15005–e15005. 1 indexed citations

Rodón, Jordi, Cesar A. Perez, Kit Man Wong, et al.. (2021). PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.. Journal of Clinical Oncology. 39(15_suppl). 3019–3019. 26 indexed citations

Li, Chunze, Rajeev Menon, Markus Walles, et al.. (2021). Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. Clinical Pharmacology & Therapeutics. 112(4). 754–769. 12 indexed citations

Mittapalli, Rajendar K., Ken Liao, Jason H. Williams, Rameshraja Palaparthy, & Donghua Yin. (2021). Optimal dose selection in oncology biologics development: Need for a paradigm shift.. Journal of Clinical Oncology. 39(15_suppl). 3093–3093.

10.

Zhang, Yao, Hua Shen, Ken Liao, et al.. (2020). Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation. Frontiers in Oncology. 10. 504381–504381. 2 indexed citations

11.

Li, Yingjia, et al.. (2020). MicroRNA-7 inhibits hepatocellular carcinoma cell invasion and metastasis by regulating Atg5-mediated autophagy. Translational Cancer Research. 9(6). 3965–3972. 12 indexed citations

12.

Li, Tianya, Ken Liao, Yue Gao, et al.. (2017). Wheat Ammonium Transporter (AMT) Gene Family: Diversity and Possible Role in Host–Pathogen Interaction with Stem Rust. Frontiers in Plant Science. 8. 1637–1637. 45 indexed citations

13.

Shen, Hongbing, et al.. (2017). In utero exposure of high-dose di-n-butyl phthalate resulted in opposite effects on testicular cell apoptosis in late embryonic and pubertal male rat offspring. Human & Experimental Toxicology. 36(12). 1236–1247. 8 indexed citations

14.

Liao, Ken, Kuen‐Bao Chen, Wen‐Yuan Lee, et al.. (2014). Ligand‐Based and Structure‐Based Investigation for Alzheimer’s Disease from Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine. 2014(1). 364819–364819. 50 indexed citations

15.

Yang, Yuching, Bruce C. Allen, Yu‐Mei Tan, Ken Liao, & Harvey J. Clewell. (2010). Bayesian Analysis of A Rat Formaldehyde DNA–Protein Cross-Link Model. Journal of Toxicology and Environmental Health. 73(12). 787–806. 3 indexed citations

16.

Zhu, Yingjian, Juntao Jiang, Jie Zhang, et al.. (2009). Molecular and toxicologic research in newborn hypospadiac male rats following in utero exposure to di-n-butyl phthalate (DBP). Toxicology. 260(1-3). 120–125. 38 indexed citations

17.

Dobrev, Ivan D., Andy Nong, Ken Liao, et al.. (2008). Assessing Kinetic Determinants for Metabolism and Oral Uptake of Octamethylcyclotetrasiloxane (D₄) from Inhalation Chamber Studies. Inhalation Toxicology. 20(4). 361–373. 15 indexed citations

18.

Tan, Yu‐Mei, Ken Liao, & Harvey J. Clewell. (2006). Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. Journal of Exposure Science & Environmental Epidemiology. 17(7). 591–603. 115 indexed citations

19.

Tan, Yu‐Mei, et al.. (2006). Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform. Journal of Toxicology and Environmental Health. 69(18). 1727–1756. 87 indexed citations

20.

Andersen, Melvin E., Roman Lutz, Ken Liao, & Werner K. Lutz. (2005). Dose-Incidence Modeling: Consequences of Linking Quantal Measures of Response to Depletion of Critical Tissue Targets. Toxicological Sciences. 89(1). 331–337. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact